Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
暂无分享,去创建一个
L. Diaz | P. Ascierto | Y. Bang | A. Joe | S. Piha-Paul | A. Hansen | M. Shah | H. Chung | J. López-Martín | N. Penel | A. Marabelle | D. Le | M. Gottfried | J. Delord | T. Doi | S. Pruitt | R. Geva | B. Gao | A. D. Di Giacomo | R. Ghori | A. De Jesus-Acosta | R. S. Frommer | M. Shah
[1] J. Chan,et al. Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer , 2020, Gynecologic oncology reports.
[2] C. Rudin,et al. Targeted Therapies and Biomarkers in Small Cell Lung Cancer , 2020, Frontiers in Oncology.
[3] F. Petrelli,et al. Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis. , 2020, JAMA oncology.
[4] C. Sautès-Fridman,et al. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies , 2020, Frontiers in Immunology.
[5] F. Roviello,et al. MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy , 2020, Journal of clinical medicine.
[6] Ahmet Zehir,et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Joe,et al. Association of PD-L1 expression with prognosis among patients with 10 select cancers. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] M. Arends,et al. Lynch syndrome – cancer pathways, heterogeneity and immune escape , 2018, The Journal of pathology.
[9] B. Taylor,et al. Pan-cancer microsatellite instability to predict for presence of Lynch syndrome. , 2018, Journal of Clinical Oncology.
[10] B. Besse,et al. New windows open for immunotherapy in lung cancer , 2018, Nature.
[11] Li Yan,et al. Precision medicine becomes reality—tumor type-agnostic therapy , 2018, Cancer communications.
[12] P. Keegan,et al. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. , 2017, The New England journal of medicine.
[13] Russell Bonneville,et al. Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.
[14] J. Desai,et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.
[15] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[16] D. D. de Alwis,et al. Evaluation of dosing strategy for pembrolizumab for oncology indications , 2017, Journal of Immunotherapy for Cancer.
[17] P. Park,et al. A molecular portrait of microsatellite instability across multiple cancers , 2016, Nature Communications.
[18] L. Diaz,et al. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. , 2016, The oncologist.
[19] James R. Eshleman,et al. Microsatellite Instability as a Biomarker for PD-1 Blockade , 2016, Clinical Cancer Research.
[20] Lauren L. Ritterhouse,et al. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. , 2015, JAMA oncology.
[21] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Taube,et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.
[23] Jeffrey J Meyer,et al. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012. (5) , 2013 .
[24] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[25] H. Lehrach,et al. Somatic Mutation Profiles of MSI and MSS Colorectal Cancer Identified by Whole Exome Next Generation Sequencing and Bioinformatics Analysis , 2010, PloS one.
[26] K. Kinzler,et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.